News | October 13, 2022
Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
Sud has more than 32 years of work experience with different companies like Clivient, Jubilant Life Sciences, Piramal Enterprises, Parabolic Drugs, Orchid Chemicals and Pharmaceuticals, Ranbaxy Labs, and Lupin
The companies will leverage their respective proprietary technology platforms
One in two women with advanced ovarian cancer has an HRD-positive tumor
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
Subscribe To Our Newsletter & Stay Updated
